|John F. Milligan, PhD|
President and Chief Executive Officer
Dr. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He was appointed President in 2008, and from 2007 to 2016 served in the role of Chief Operating Officer as well. He previously held multiple leadership roles within Gilead, including the position of Chief Financial Officer from 2002 to 2007.
|John C. Martin, PhD|
|Dr. Martin joined Gilead Sciences in 1990 and was appointed Executive Chairman in March 2016. He served as Chairman and Chief Executive Officer from June 2008 through March 2016 and President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.|
Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute (CHI). He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Directors for CHI, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago, an MBA from Golden Gate University and a bachelor’s of science degree in chemical engineering from Purdue University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
|Gregg H. Alton|
Executive Vice President, Corporate and Medical Affairs
Gregg Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as General Counsel. In his current role, Mr. Alton is responsible for legal affairs, government affairs, medical affairs, public affairs and emerging market activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies.
Mr. Alton is a member of the boards of the AIDS Institute, the Boys and Girls Clubs of Oakland and Celladon Corporation. He is also a member of the U.S. Government's Industry Trade Advisory Committee on Intellectual Property Rights, the advisory boards of UCSF Global Health Group, USC Schaeffer Center for Health Policy and Economics, Pharmozyme, Inc. and the Dean’s Advisory Council at Stanford Law School. In addition, he serves on Partners In Health’s Board of Trustees. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.
|Norbert W. Bischofberger, PhD|
Executive Vice President, Research and Development and Chief Scientific Officer
|Dr. Bischofberger joined Gilead Sciences in 1990 and has served Executive Vice President for Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 until 1990.
Dr. Bischofberger received a PhD in organic chemistry from Zurich’s Eidgenossische Technische Hochshule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts.
|Andrew Cheng, MD, PhD |
Executive Vice President, Clinical Research and Development Operations
|Dr. Cheng joined Gilead Sciences in 1999 and was appointed to his current role of Executive Vice President, Clinical Research and Development Operations in January 2015. In this role, he is responsible for clinical development for the company’s development-stage programs in HIV/AIDS. He also oversees Gilead’s biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs activities. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles.|
Dr. Cheng is a member of the board of the Global Virus Network, based in Baltimore, Maryland. He received his bachelor’s degree from the Johns Hopkins University and his medical degree and PhD in Cellular and Molecular Biology from Columbia University.
|William A. Lee, PhD|
Executive Vice President Research
Dr. Lee joined Gilead Sciences in 1991 as Director, Pharmaceutical Product Development. In 2015, he was appointed Executive Vice President, Research and has been responsible for the expansion of the company’s research and preclinical activities across a range of therapeutic areas, including HIV, liver diseases, hematology and oncology, inflammation and respiratory diseases and cardiovascular conditions. Prior to joining Gilead, Dr. Lee was head of Drug Delivery at California Biotechnology, Inc. and began his career as a research scientist at Syntex Research in Palo Alto, California.
|John McHutchison, MD|
Executive Vice President, Clinical Research
|Dr. McHutchison joined Gilead in 2010. From 2010 to 2013, he served as Senior Vice President, Liver Disease Therapeutics. In his current role, he is responsible for Gilead’s development programs in liver diseases, oncology, respiratory diseases and inflammation. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. |
Dr. McHutchison received bachelor of medicine and bachelor of surgery degrees from the University of Melbourne, Australia, and completed his residency in internal medicine and a fellowship in gastroenterology at the Royal Melbourne Hospital. He is also a member of the Royal Australasian College of Physicians.
Executive Vice President and General Counsel
Brett Pletcher joined Gilead Sciences in 2005 and is currently Executive Vice President and General Counsel overseeing the company’s legal organization. Prior to joining Gilead, Mr. Pletcher was a partner in the law firm of Gunderson Dettmer, LLP, where he focused on providing corporate and securities services to emerging growth public and private companies and venture capital investors.
|Martin B. Silverstein, MD|
Executive Vice President, Strategy
Dr. Silverstein joined Gilead in 2016 to oversee the company’s corporate development, commercial planning and alliance management functions. Prior to this, he held the role of Executive Vice President and Chief Strategy Officer at Anthem, and spent 28 years in roles of increasing responsibility at The Boston Consulting Group, where he was a Senior Partner and Managing Director and served as the Global Leader of its Health Care Practice.
Dr. Silverstein received a medical degree from Yale University, an MBA from Harvard Business School and a bachelor’s degree from the University of Pennsylvania. He completed his internal medicine residency at Boston's Beth Israel Hospital and is board certified in Internal Medicine. Dr. Silverstein is a board member of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania.
|Robin L. Washington|
Executive Vice President and Chief Financial Officer
Ms. Washington joined Gilead in 2008 as Senior Vice President and Chief Financial Officer where she oversees the Global Finance and Information Technology organizations. Ms. Washington was promoted to Executive Vice President in 2014. Ms. Washington was previously Chief Financial Officer of Hyperion Solutions, which was acquired by Oracle Corporation in March 2007. Prior to that, Ms. Washington served in a number of executive positions with PeopleSoft, most recently in the role of Senior Vice President and Corporate Controller. Ms. Washington previously served on the Board of Directors of Tektronix, Inc. (acquired by Danaher), the Board of Directors of MIPS Technologies Inc. (acquired by Imagination), and currently is a member of the Board of Directors of Honeywell International, the Board of Directors of Salesforce.com, and the Board of Visitors, Graziadio School of Business and Management, Pepperdine University.
Ms. Washington is a certified public accountant and holds a bachelor's degree in business administration from the University of Michigan and a MBA from Pepperdine University.
|Katie L. Watson|
Senior Vice President, Human Resources
Ms. Watson joined Gilead in February 2003 to manage compensation and HR information systems. In 2006 she was promoted to Senior Director of Total Rewards, and was appointed to Vice President of Employee Development and Rewards in 2012.Ms. Watson currently serves as Senior Vice President Human Resources. Before joining Gilead she was Manager of Compensation for Applied Biosystems (formerly Applera Corporation), led the HR consulting practice for TriNet and worked as an HR Business Partner for DE Shaw & Co.
Ms. Watson holds a degree in Psychology from the University of California at San Diego and a master's in Organizational Psychology from Columbia University.
|Taiyin Yang, PhD|
Executive Vice President, Pharmaceutical Development and Manufacturing
|Dr. Yang joined Gilead in 1993 and was appointed to her current role of Executive Vice President, Pharmaceutical Development and Manufacturing in January 2015. She is responsible for the chemistry, manufacturing and control operations of small molecules and biologics encompassing process development, production, supply chain management, analytical operations, laboratory information and quality assurance for Gilead’s investigational and commercial products. Prior to joining Gilead, Dr. Yang was Director of Analytical Chemistry at Syntex.|
Dr. Yang is a member of the American Association of Pharmaceutical Scientists, a member of the American Chemical Society and a member of the Drug Information Association. She received her bachelor’s degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California.
|Kevin Young CBE|
Chief Operating Officer
Kevin Young joined Gilead Sciences in 2004 and was appointed Chief Operating Officer in May 2016. He served as Executive Vice President of Commercial Operations from 2004 through 2014, and from 2014 to 2016 served as senior advisor to the company. Prior to Gilead, Mr. Young spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. During his 12 years at Amgen, he held a number of positions in Europe and the United States, including Head of the U.S. Inflammation Business Unit, leading the re-launch of Enbrel® following the acquisition of Immunex Corporation.
Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England. In 2011 he was appointed a Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his services to the healthcare and pharmaceutical industries.